Journal article
Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity
Abstract
The development of neutralizing antibodies to factor VIII (FVIII) is the most serious complication of therapy for haemophilia A. There is now excellent documentation that a large number of both genetic and environmental factors contribute to the risk of FVIII inhibitor incidence. One of the environmental factors that has been proposed as an influence on this complication is the occurrence of FVIII product switching. There are only a small …
Authors
Matino D; Lillicrap D; Astermark J; Dolan G; Kessler C; Lambert T; Makris M; O'Donnell J; Pipe S; Santagostino E
Journal
Haemophilia, Vol. 20, No. 2, pp. 200–206
Publisher
Wiley
Publication Date
March 2014
DOI
10.1111/hae.12283
ISSN
1351-8216